Gregory Norden
At a glance: Gregory Norden is Director at Royalty Pharma (RPRX). Their latest SEC Form 4, filed May 15, 2026, reported a sale of $161K. On file: 0 purchase lines ($0) and 1 sale line ($161K).
Disclosed holdings: about $13.0M of RPRX stock: 191,803 shares reported on their latest Form 4 (filed May 15, 2026), valued at the Nov 19, 2026 close of $67.86. This counts only RPRX shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Royalty Pharma plc (RPRX)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Gregory Norden's InsiderPrint
2 trades from SEC Form 4 filings, 2023 to 2026, drawn as one fingerprint.
- Bump outward: a purchase (1)
- Dent inward: a sale (1)
- One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| May 15SEC | RPRXRoyalty Pharma plc | Sell Plan | 3,045191,803 held (−2%) | $53.00 | $161K | +28.0% |
- Sell
Director Gregory Norden sold $161K of RPRX at $53.00 — pre-scheduled 10b5-1 plan sale.
Follow Gregory Norden
Get one email when Gregory Norden files a new purchase or sale. Free.
At most one email a day about Gregory Norden, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.